UNLABELLED: Tick-borne encephalitis (TBE) virus is an important human-pathogenic flavivirus endemic in large parts of Europe and Central and Eastern Asia. Neutralizing antibodies specific for the viral envelope protein E are believed to mediate long-lasting protection after natural infection and vaccination. To study the specificity and individual variation of human antibody responses, we developed immunoassays with recombinant antigens representing viral surface protein domains and domain combinations. These allowed us to dissect and quantify antibody populations of different fine specificities in sera of TBE patients and vaccinees. Postinfection and postvaccination sera both displayed strong individual variation of antibody titers as well as the relative proportions of antibodies to different domains of E, indicating that the immunodominance patterns observed were strongly influenced by individual-specific factors. The contributions of these antibody populations to virus neutralization were quantified by serum depletion analyses and revealed a significantly biased pattern. Antibodies to domain III, in contrast to what was found in mouse immunization studies with TBE and other flaviviruses, did not play any role in the human neutralizing antibody response, which was dominated by antibodies to domains I and II. Importantly, most of the neutralizing activity could be depleted from sera by a dimeric soluble form of the E protein, which is the building block of the icosahedral herringbone-like shell of flaviviruses, suggesting that antibodies to more complex quaternary epitopes involving residues from adjacent dimers play only a minor role in the total response to natural infection and vaccination in humans. IMPORTANCE: Tick-borne encephalitis (TBE) virus is a close relative of yellow fever, dengue, Japanese encephalitis, and West Nile viruses and distributed in large parts of Europe and Central and Eastern Asia. Antibodies to the viral envelope protein E prevent viral attachment and entry into cells and thus mediate virus neutralization and protection from disease. However, the fine specificity and individual variation of neutralizing antibody responses are currently not known. We have therefore developed new in vitro assays for dissecting the antibody populations present in blood serum and determining their contribution to virus neutralization. In our analysis of human postinfection and postvaccination sera, we found an extensive variation of the antibody populations present in sera, indicating substantial influences of individual-specific factors that control the specificity of the antibody response. Our study provides new insights into the immune response to an important human pathogen that is of relevance for the design of novel vaccines.

Department of Virology Medical University of Vienna Vienna Austria

Hospital Ceske Budejovice Department of Infectious Diseases Ceske Budejovice Czech Republic

Institute of Environmental Health Medical University of Vienna Vienna Austria

Zobrazit více v PubMed

Simmonds P, Becher P, Collett MS, Gould EA, Heinz FX, Meyers G, Monath T, Pletnev A, Rice CM, Stiasny K, Thiel HJ, Weiner A, Bukh J. 2011. Family Flaviviridae. In King AMQ, Adams MJ, Lefkowitz EJ, Carstens EB. (ed), Virus taxonomy, vol IX Report of the International Committee on Taxonomy of Viruses Elsevier Academic Press, San Diego, CA.

Monath TP, Gershman M, Staples JE, Barrett ADT. 2013. Yellow fever vaccine, p 870–968 In Plotkin SA, Orenstein WA, Offit PA. (ed), Vaccines, 6th ed. Elsevier Saunders, Philadelphia, PA.

Halstead SB, Jacobson J, Dubischar-Kastner K. 2013. Japanese encephalitis vaccine, p 312–351 In Plotkin SA, Orenstein WA, Offit PA. (ed), Vaccines, 6th ed. Elsevier Saunders, Philadelphia, PA.

Barrett PN, Portsmouth D, Ehrlich HJ. 2013. Tick-borne encephalitis virus vaccines, p 773–788 In Plotkin SA, Orenstein WA, Offit PA. (ed), Vaccines, 6th ed. Elsevier Saunders, Philadelphia, PA.

Halstead SB, Thomas SJ. 2013. Dengue vaccines, p 1042–1051 In Plotkin SA, Orenstein WA, Offit PA. (ed), Vaccines, 6th ed. Elsevier Saunders, Philadelphia, PA.

Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. 2008. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4:229–238. 10.1016/j.chom.2008.08.004. PubMed DOI PMC

Pierson TC, Diamond MS. 2008. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev. Mol. Med. 10:e12. 10.1017/S1462399408000665. PubMed DOI PMC

Gollins SW, Porterfield JS. 1986. A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature 321:244–246. 10.1038/321244a0. PubMed DOI

Dowd KA, Pierson TC. 2011. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology 411:306–315. 10.1016/j.virol.2010.12.020. PubMed DOI PMC

Slifka MK, Matloubian M, Ahmed R. 1995. Bone marrow is a major site of long-term antibody production after acute viral infection. J. Virol. 69:1895–1902. PubMed PMC

Benner R, Hijmans W, Haaijman JJ. 1981. The bone marrow: the major source of serum immunoglobulins, but still a neglected site of antibody formation. Clin. Exp. Immunol. 46:1–8. PubMed PMC

Lavinder JJ, Wine Y, Giesecke C, Ippolito GC, Horton AP, Lungu OI, Hoi KH, Dekosky BJ, Murrin EM, Wirth MM, Ellington AD, Dorner T, Marcotte EM, Boutz DR, Georgiou G. 2014. Identification and characterization of the constituent human serum antibodies elicited by vaccination. Proc. Natl. Acad. Sci. U. S. A. 111:2259–2264. 10.1073/pnas.1317793111. PubMed DOI PMC

Dormitzer PR, Ulmer JB, Rappuoli R. 2008. Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol. 26:659–667. 10.1016/j.tibtech.2008.08.002. PubMed DOI PMC

Lindenbach DB, Murray CL, Thiel HJ, Rice CM. 2013. Flaviviridae. In Knipe DM, Howley PM. (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.

Pierson TC, Diamond MS. 2013. Flaviviruses. In Knipe DM, Howley PM. (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.

Stiasny K, Kiermayr S, Holzmann H, Heinz FX. 2006. Cryptic properties of dominant flavivirus cross-reactive antigenic sites. J. Virol. 80:9557–9568. 10.1128/JVI.00080-06. PubMed DOI PMC

Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi BE, Olshevsky U, Fremont DH, Pierson TC, Diamond MS. 2006. Antibody recognition and neutralization determinants on domains I and II of West Nile virus envelope protein. J. Virol. 80:12149–12159. 10.1128/JVI.01732-06. PubMed DOI PMC

Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, King CC, Wu HC, Chang GJ, Wang WK. 2008. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J. Virol. 82:6631–6643. 10.1128/JVI.00316-08. PubMed DOI PMC

Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F. 2010. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271–283. 10.1016/j.chom.2010.08.007. PubMed DOI PMC

Davies DR, Padlan EA, Sheriff S. 1990. Antibody-antigen complexes. Annu. Rev. Biochem. 59:439–473. 10.1146/annurev.bi.59.070190.002255. PubMed DOI

Sundberg EJ, Mariuzza RA. 2002. Molecular recognition in antibody-antigen complexes. Adv. Protein Chem. 61:119–160. 10.1016/S0065-3233(02)61004-6. PubMed DOI

Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, Kramer RA, Clijsters-van der Horst M, de Jong M, Jongeneelen M, Thijsse S, Smit R, Visser TJ, Bijl N, Marissen WE, Loeb M, Kelvin DJ, Preiser W, ter Meulen J, de Kruif J. 2006. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile virus. J. Virol. 80:6982–6992. 10.1128/JVI.00551-06. PubMed DOI PMC

Goncalvez AP, Purcell RH, Lai CJ. 2004. Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein. J. Virol. 78:12919–12928. 10.1128/JVI.78.23.12919-12928.2004. PubMed DOI PMC

Kaufmann B, Vogt MR, Goudsmit J, Holdaway HA, Aksyuk AA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG. 2010. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc. Natl. Acad. Sci. U. S. A. 107:18950–18955. 10.1073/pnas.1011036107. PubMed DOI PMC

Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT, Yip A, Schul W, Aung M, Kostyuchenko VA, Leo YS, Chan SH, Smith KG, Chan AH, Zou G, Ooi EE, Kemeny DM, Tan GK, Ng JK, Ng ML, Alonso S, Fisher D, Shi PY, Hanson BJ, Lok SM, MacAry PA. 2012. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci. Transl. Med. 4:139ra83. 10.1126/scitranslmed.3003888. PubMed DOI

de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, Jr, de Silva AM. 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl. Acad. Sci. U. S. A. 109:7439–7444. 10.3410/f.716398009.791803068. PubMed DOI PMC

Vratskikh O, Stiasny K, Zlatkovic J, Tsouchnikas G, Jarmer J, Karrer U, Roggendorf M, Roggendorf H, Allwinn R, Heinz FX. 2013. Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog. 9:e1003458. 10.1371/journal.ppat.1003458. PubMed DOI PMC

Kunz C. 1996. Epidemiology of tick-borne encephalitis and the impact of vaccination on the incidence of disease, p 143–149 In Eibl MM, Huber C, Peter HH, Wahn V. (ed), Symposium in immunology, vol V Springer Verlag, Heidelberg, Germany.

Heinz FX, Holzmann H, Essl A, Kundi M. 2007. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 25:7559–7567. 10.1016/j.vaccine.2007.08.024. PubMed DOI

Heinz FX, Stiasny K, Holzmann H, Grgic-Vitek M, Kriz B, Essl A, Kundi M. 2013. Vaccination and tick-borne encephalitis, central Europe. Emerg. Infect. Dis. 19:69–76. 10.3201/eid1901.120458. PubMed DOI PMC

Heinz FX, Kunz C. 1981. Homogeneity of the structural glycoprotein from European isolates of tick-borne encephalitis virus: comparison with other flaviviruses. J. Gen. Virol. 57:263–274. 10.1099/0022-1317-57-2-263. PubMed DOI

Elshuber S, Allison SL, Heinz FX, Mandl CW. 2003. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J. Gen. Virol. 84:183–191. 10.1099/vir.0.18723-0. PubMed DOI

Zlatkovic J, Stiasny K, Heinz FX. 2011. Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice. J. Virol. 85:1994–2003. 10.1128/JVI.01886-10. PubMed DOI PMC

Kiermayr S, Stiasny K, Heinz FX. 2009. Impact of quaternary organization on the antigenic structure of the tick-borne encephalitis virus envelope glycoprotein E. J. Virol. 83:8482–8491. 10.1128/JVI.00660-09. PubMed DOI PMC

Allison SL, Stadler K, Mandl CW, Kunz C, Heinz FX. 1995. Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J. Virol. 69:5816–5820. PubMed PMC

Maizel JV. 1971. Polyacrylamide gel electrophoresis of viral proteins. Methods Virol. 5:179–246. 10.1016/B978-0-12-470205-9.50011-3. DOI

Stiasny K, Allison SL, Schalich J, Heinz FX. 2002. Membrane interactions of the tick-borne encephalitis virus fusion protein E at low pH. J. Virol. 76:3784–3790. 10.1128/JVI.76.8.3784-3790.2002. PubMed DOI PMC

Heinz FX, Stiasny K, Puschner-Auer G, Holzmann H, Allison SL, Mandl CW, Kunz C. 1994. Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology 198:109–117. 10.1006/viro.1994.1013. PubMed DOI

Frey A, Di Canzio J, Zurakowski D. 1998. A statistically defined endpoint titer determination method for immunoassays. J. Immunol. Methods 221:35–41. 10.1016/S0022-1759(98)00170-7. PubMed DOI

Stiasny K, Aberle JH, Keller M, Grubeck-Loebenstein B, Heinz FX. 2012. Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis. PLoS One 7:e34145. 10.1371/journal.pone.0034145. PubMed DOI PMC

Heinz FX, Tuma W, Guirakhoo F, Kunz C. 1986. A model study of the use of monoclonal antibodies in capture enzyme immunoassays for antigen quantification exploiting the epitope map of tick-borne encephalitis virus. J. Biol. Stand. 14:133–141. 10.1016/0092-1157(86)90032-6. PubMed DOI

Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375:291–298. 10.1038/375291a0. PubMed DOI

Zlatkovic J, Tsouchnikas G, Jarmer J, Koessl C, Stiasny K, Heinz FX. 2013. Aluminum hydroxide influences not only the extent but also the fine specificity and functional activity of antibody responses to tick-borne encephalitis virus in mice. J. Virol. 87:12187–12195. 10.1128/JVI.01690-13. PubMed DOI PMC

Fibriansah G, Tan JL, Smith SA, de Alwis AR, Ng TS, Kostyuchenko VA, Ibarra KD, Wang J, Harris E, de Silva A, Crowe JE, Jr, Lok SM. 2014. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol. Med. 6:358–371. 10.1002/emmm.201303404. PubMed DOI PMC

Allison SL, Stiasny K, Stadler K, Mandl CW, Heinz FX. 1999. Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E. J. Virol. 73:5605–5612. PubMed PMC

Rey FA. 2013. Dengue virus: two hosts, two structures. Nature 497:443–444. 10.1038/497443a. PubMed DOI

Dowd KA, Mukherjee S, Kuhn RJ, Pierson TC. 2014. Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition. J. Virol. 88:11726–11737. 10.1128/JVI.01140-14. PubMed DOI PMC

Nelson S, Jost CA, Xu Q, Ess J, Martin JE, Oliphant T, Whitehead SS, Durbin AP, Graham BS, Diamond MS, Pierson TC. 2008. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4:e1000060. 10.1371/journal.ppat.1000060. PubMed DOI PMC

Mukherjee S, Dowd KA, Manhart CJ, Ledgerwood JE, Durbin AP, Whitehead SS, Pierson TC. 2014. Mechanism and significance of cell type-dependent neutralization of flaviviruses. J. Virol. 88:7210–7220. 10.1128/JVI.03690-13. PubMed DOI PMC

Wahala WM, Silva AM. 2011. The human antibody response to dengue virus infection. Viruses 3:2374–2395. 10.3390/v3122374. PubMed DOI PMC

Lin HE, Tsai WY, Liu IJ, Li PC, Liao MY, Tsai JJ, Wu YC, Lai CY, Lu CH, Huang JH, Chang GJ, Wu HC, Wang WK. 2012. Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl. Trop. Dis. 6:e1447. 10.1371/journal.pntd.0001447. PubMed DOI PMC

VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC. 2013. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. PLoS Pathog. 9:e1003761. 10.1371/journal.ppat.1003761. PubMed DOI PMC

Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, Crowe JE., Jr 2013. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J. Infect. Dis. 207:1898–1908. 10.1093/infdis/jit119. PubMed DOI PMC

Messer WB, de Alwis R, Yount BL, Royal SR, Huynh JP, Smith SA, Crowe JE, Jr, Doranz BJ, Kahle KM, Pfaff JM, White LJ, Sariol CA, de Silva AM, Baric RS. 2014. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc. Natl. Acad. Sci. U. S. A. 111:1939–1944. 10.1073/pnas.1317350111. PubMed DOI PMC

Lai CJ, Goncalvez AP, Men R, Wernly C, Donau O, Engle RE, Purcell RH. 2007. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. J. Virol. 81:12766–12774. 10.1128/JVI.01420-07. PubMed DOI PMC

Crill WD, Hughes HR, Delorey MJ, Chang GJ. 2009. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 4:e4991. 10.1371/journal.pone.0004991. PubMed DOI PMC

Mathonet P, Ullman CG. 2013. The application of next generation sequencing to the understanding of antibody repertoires. Front. Immunol. 4:265. 10.3389/fimmu.2013.00265. PubMed DOI PMC

Baumgarth N. 2013. How specific is too specific? B-cell responses to viral infections reveal the importance of breadth over depth. Immunol. Rev. 255:82–94. 10.1111/imr.12094. PubMed DOI PMC

Chan TD, Brink R. 2012. Affinity-based selection and the germinal center response. Immunol. Rev. 247:11–23. 10.1111/j.1600-065X.2012.01118.x. PubMed DOI

Wine Y, Boutz DR, Lavinder JJ, Miklos AE, Hughes RA, Hoi KH, Jung ST, Horton AP, Murrin EM, Ellington AD, Marcotte EM, Georgiou G. 2013. Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response. Proc. Natl. Acad. Sci. U. S. A. 110:2993–2998. 10.1073/pnas.1213737110. PubMed DOI PMC

Cardosa MJ, Wang SM, Sum MS, Tio PH. 2002. Antibodies against prM protein distinguish between previous infection with dengue and Japanese encephalitis viruses. BMC Microbiol. 2:9. 10.1186/1471-2180-2-9. PubMed DOI PMC

Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G. 2010. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328:745–748. 10.1126/science.1185181. PubMed DOI PMC

Tsai WY, Lai CY, Wu YC, Lin HE, Edwards C, Jumnainsong A, Kliks S, Halstead S, Mongkolsapaya J, Screaton GR, Wang WK. 2013. High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. J. Virol. 87:12562–12575. 10.1128/JVI.00871-13. PubMed DOI PMC

Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, Loeb M, Throsby M, Fremont DH, Pierson TC, Diamond MS. 2007. Induction of epitope-specific neutralizing antibodies against West Nile virus. J. Virol. 81:11828–11839. 10.1128/JVI.00643-07. PubMed DOI PMC

Fibriansah G, Ng TS, Kostyuchenko VA, Lee J, Lee S, Wang J, Lok SM. 2013. Structural changes in dengue virus when exposed to a temperature of 37 degrees C. J. Virol. 87:7585–7592. 10.1128/JVI.00757-13. PubMed DOI PMC

Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC. 2011. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog. 7:e1002111. 10.1371/journal.ppat.1002111. PubMed DOI PMC

Zhang X, Sheng J, Plevka P, Kuhn RJ, Diamond MS, Rossmann MG. 2013. Dengue structure differs at the temperatures of its human and mosquito hosts. Proc. Natl. Acad. Sci. U. S. A. 110:6795–6799. 10.1073/pnas.1304300110. PubMed DOI PMC

Pierson TC, Kuhn RJ. 2012. Capturing a virus while it catches its breath. Structure 20:200–202. 10.1016/j.str.2012.01.014. PubMed DOI PMC

Cockburn JJ, Navarro Sanchez ME, Fretes N, Urvoas A, Staropoli I, Kikuti CM, Coffey LL, Arenzana Seisdedos F, Bedouelle H, Rey FA. 2012. Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure 20:303–314. 10.1016/j.str.2012.01.001. PubMed DOI

Kostyuchenko VA, Chew PL, Ng TS, Lok SM. 2014. Near-atomic resolution cryo-electron microscopic structure of dengue serotype 4 virus. J. Virol. 88:477–482. 10.1128/JVI.02641-13. PubMed DOI PMC

Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, Diamond MS, Kuhn RJ, Rossmann MG. 2008. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15:312–317. 10.1038/nsmb.1382. PubMed DOI

Metz B, Kersten GF, Baart GJ, de Jong A, Meiring H, ten Hove J, van Steenbergen MJ, Hennink WE, Crommelin DJ, Jiskoot W. 2006. Identification of formaldehyde-induced modifications in proteins: reactions with insulin. Bioconjug. Chem. 17:815–822. 10.1021/bc050340f. PubMed DOI

Fraenkel-Conrat H, Mecham DK. 1949. The reaction of formaldehyde with proteins; demonstration of intermolecular cross-linking by means of osmotic pressure measurements. J. Biol. Chem. 177:477–486. PubMed

Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. 2005. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J. Biol. Chem. 280:13406–13414. 10.1074/jbc.M500687200. PubMed DOI

Morefield GL, Sokolovska A, Jiang D, HogenEsch H, Robinson JP, Hem SL. 2005. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23:1588–1595. 10.1016/j.vaccine.2004.07.050. PubMed DOI

Dormitzer PR, Grandi G, Rappuoli R. 2012. Structural vaccinology starts to deliver. Nat. Rev. Microbiol. 10:807–813. 10.1038/nrmicro2893. PubMed DOI

Wong SS, Webby RJ. 2013. Traditional and new influenza vaccines. Clin. Microbiol. Rev. 26:476–492. 10.1128/CMR.00097-12. PubMed DOI PMC

Chiodi F, Weiss RA. 2014. HIV antibodies and the vaccine problem. J. Intern. Med. 275:444–455. 10.1111/joim.12225. PubMed DOI

Mukhopadhyay S, Kuhn RJ, Rossmann MG. 2005. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3:13–22. 10.1038/nrmicro1067. PubMed DOI

Li L, Lok SM, Yu IM, Zhang Y, Kuhn RJ, Chen J, Rossmann MG. 2008. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319:1830–1834. 10.1126/science.1153263. PubMed DOI

Iacono-Connors LC, Smith JF, Ksiazek TG, Kelley CL, Schmaljohn CS. 1996. Characterization of Langat virus antigenic determinants defined by monoclonal antibodies to E, NS1 and preM and identification of a protective, non-neutralizing preM-specific monoclonal antibody. Virus Res. 43:125–136. PubMed

Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung KM, Ebel GD, Kramer LD, Fremont DH, Diamond MS. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11:522–530. 10.1038/nm1240. PubMed DOI PMC